COMPLICATIONS OF HUMAN PAPILLOMA VIRUS VACCINES

Yıl 2014, Cilt: 17 Sayı: 3, 0 - 0, 01.07.2014

Türkan Gürsu Güldeniz Desteli Ali Ayhan

Öz

HPV 16/18 bivalent vaccines and HPV 6/11/16/18 quadrivalent vaccines are protective vaccines against cervical carcinoma as
prooved by many studies so far. The PATRICIA study revealed that due to cross protective effect against other types of viruses, the
preventative field of current vaccines’ are enlarged. Bivalent vaccines show dominant protection against HPV 18 than quadrivalent
vaccines. The effects and side effects of both vaccines are discussed in large case series till this day. EINSTEIN studied vaccines in
aspect of creation of immunogenic response and related complications . In the literature, short term complications are grouped as
hypersensitivity reactions, local side effects, and among long term complications there are demyelinizating diseases, autoimmune
thyroditis, endocrinopathies and other systemic diseases. In this study we rewieved current short and long term complications of
HPV vaccines.

Anahtar Kelimeler

HPV, Cervix cancer, HPV vaccine, Vaccine complications

HUMAN PAPİLLOMA VİRÜS AŞILARININ KOMPLİKASYONLARI

Öz

HPV tip 16,18 e karşı etkili bivalan ve HPV tip 6,11,16,18 e karşı etkili kuadrivalan HPV aşılarının koruyuculuğu birçok çalışma ile
kanıtlanmıştır. PATRICIA çalışması ile diğer HPV tiplerine karşı da çapraz reaksiyonlar ile aşıların koruyucu olduğu bildirilmiştir. Bivalan
aşının HPV 18’e karşı koruyuculuğu daha baskındır. Her iki aşının etkileri ve komplikasyonları birçok çalışma ve vaka serileri ile
tartışılmış, EINSTEIN’ın çalışmasında aşıların immun cevap oluşturabilmeleri ve komplikasyonları incelenmiştir. Literatürde erken
dönemde hipersensitiveite reaksiyonları, lokal etkiler ve uzun dönem etkiler arasında demiyelinizan hastalıklar, otoimmun tiroiditler,
endokrin ve sistemik hastalıklar araştırılmıştır. Biz bu çalışmamızda HPV aşılarının kısa ve uzun dönem komplikasyonlarını
inceledik

Anahtar Kelimeler

HPV, Serviks kanseri, HPV aşıları, Aşı komplikasyonları

Kaynakça

• 1. Çiçek NM, Akyürek C, Çelik C, Haberal A . Kadın Hastalıkları ve Doğum Bilgisi, Güneş Kitabevi, Ankara 2004; 679-681.
• 2. Ayhan A, Gultekin M, Dursun P Textbook of Gynaecological Oncology Güneş Kitabevi, Ankara 2010; 67-77.
• 3. Macartney KK, Clayton C, Georgousakis M, Brotherton JML. Safety of Human Papillomavirus Vaccines: A Review Drug Safety Drug Saf. 2013 ;36:393-412.
• 4. Dutch Health Council. Vaccination against cervical cancer: The Hague: Dutch Health Council;2008. Publication No:2008/08.
• 5. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC Human papillomavirus and cervical cancer. TheLancet 2013;382: 889-99
• 6. Paavonen J, Naud P, Salmeron J, et al. Efficacy of humanpapillomavirus (HPV) -16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomisedstudy in youngwomen. Lancet. 2009;374:301–14.
• 7. Centers for Disease Control and Prevention (CDC), The Food and Drug Administration (FDA), agencies of the U.S. Department of Health and Human Services. Vaccine Adverse Events Reporting System [online]. 2012. http:// vaers.hhs.gov/index (AccessedAugust, 2012).
• 8. Barbaud A, Deschildre A, Waton j, Raison-Peyron N, Trechot P. Hypersensitivityandvaccines: an update Eur J Dermatol 2013; 23: 135-41.
• 9. Castle PE, Cox JT, Palefsky JM. UpToDate: Clinical trials of human papillomavirus vaccines. 2013.
• 10. DiMiceli L, Pool V, Kelso JM et al Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006;24:703-7.
• 11. Kelso MJ. UpToDate: Allergic reactions to vaccine 2013.
• 12. Kang LW, Crawford N, Tang ML Hypersensitivit yreacitons to humanpapillomavirus vaccine in Australian schoolgirls: retrospective cohort study. MBJ 2008;337:a2642
• 13. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lyod S New South Wales Health HPV Adverse Event Pane. Anaphylaxis following quadrivalent humanpapillomavirus vaccination. CMAJ 2008;179:525-33.
• 14. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. ArchDis Child. 2012; 97: 913-5.
• 15. Arie S. Chile votes to ban thiomersal in vaccines despite opposition from doctors and scientists. BMJ. 2014;348:1355.
• 16. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papillomavirus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr InfectDis J. 2007 ; 26: 979-84.
• 17. vanKlooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.Vaccine. 2011 Jun 20;29(28):4601-7
• 18. Crawford NW, Clothier HJ, Elia S, Lazzaro T, Royle J, Buttery JP Syncope and seizures following human papillomavirus vaccination: a retrospective case series MJA 2011;194(1):16-18.
• 19. Gee J, Naleway A, Shui I, et al. Weintraub ES. Monitoringthesafety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Data Vaccine. 2011;29(46):8279-84.
• 20. Centre for Disease Control. Recommendations on the use of quadrivalent humanpapillomavirus vaccine in males Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60:1705–8.
• 21. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5:705–719.
• 22. Einstein MH, Baron M, Levin MJ ,Chatterjee A,Fox B, Scholar S, Rosen J Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Hum Vaccin. 2011 December; 7(12): 1343–1358.
• 23. DellaCorte C, Carlucci A, Francalanci P, Alisi A, Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011;29:4654-4656.
• 24. Cerami C, Corbo M, P, Ccolo G, Iannaccone S Autoimmune Neuromyotonia Following Human Papillomavirus Vaccination. Muscle&Nerve 2013; :466-467
• 25. Watanabe T, Hashidate H, Hirayama Y. Kikuchi-Fujimoto disease following vaccination against human papillomavirus infection and Japanese encephalitis Eur J Pediatrics 2012;171:1409-11.
• 26. Sutton I, Lahoriai R, Tan IL, Clouston P, Barnett MH CNS demyelination and quadrivalent HPV vaccination. Multiple Sclerosis 2009;15:116-19.
• 27. Deeber P, DeMunter P, Bruyninckx F, Devlieger R Brachial plexus neuritis following HPV vaccination Vaccine 2008;26:4417-19.
• 28. Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J InternMed. 2013 Nov 8. doi: 10.1111/ joim.12155.
• 29. Moscicki AB, Wheeler C, Romanowski B, Hedrick J, Gall S, Ferris D Anamnestic response elicited by a fourth dose of the HPV-16/18 adjuvanted vaccine in young women; EUROGIN; February 17–20, 2010; Monte Carlo, Monaco. 2010.